CSL share price lower despite UK Government deal

CSL has got the UK's back if there's another pandemic.

| More on:
A smiling young woman sits on a bridge in London checking her online shopping, indicating share price movement for ASX BNPL shares overseas

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is falling on Wednesday.

In morning trade, the biotherapeutics giant's shares are down 1.5% to $251.94.

Why is the CSL share price falling?

Investors have been selling the company's shares today after broad market weakness offset the release of some potentially positive news.

At the time of writing, the ASX 200 index is down 0.25% following a very poor night of trade on Wall Street.

What did CSL announce?

Overnight, CSL announced a deal between its CSL Seqirus business and the UK government.

According to the release, CSL Seqirus will develop and supply pandemic influenza vaccines in the event of an influenza pandemic.

Under the terms of the agreement, should an influenza pandemic be declared, the UK government would have the option to purchase more than 100 million doses of pandemic vaccines from the CSL Seqirus manufacturing plant in Liverpool in a rapid timeframe.

CSL Seqirus' global executive director for pandemic, Marc Lacey, commented:

CSL Seqirus is a global leader in pandemic influenza preparedness, and we're pleased the UK government will continue to partner with us in preparing to provide protection against the potential of a flu pandemic. This agreement will help to ensure the UK maintains robust preparedness and rapid response capabilities for this potential future threat.

Lorna Meldrum from CSL Seqirus added:

CSL Seqirus has been an active and reliable partner to the UK across pandemic influenza vaccines for many years. We are proud to play a continued part in ensuring ever higher levels of influenza preparedness in the UK and globally.

No financial terms were disclosed for the deal.

While this is good news for the company, let's hope that CSL Seqirus won't be needed!

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

Why Mesoblast shares could still be dirt cheap even after 700% gain

This biotech has been on fire but the gains may not be over yet according to Bell Potter.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

The 'crucial' growth metric that makes CSL shares a buy today

A leading expert points to a critical growth metric that could boost CSL shares in 2025.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 biotech stock is jumping 7% on big news

What is getting investors excited today? Let's find out.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Why is this ASX 200 healthcare share tanking 10% on Tuesday?

This ASX radiopharmaceutical company's 1H FY25 report appears to have rattled investors.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why

Investors are piling into Mesoblast shares on Monday. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Up 162% in a year, Pro Medicus share price leaping higher today on major US news

ASX 200 investors are reacting positively to Pro Medicus’ latest US news.

Read more »